Shibuta, T.; Shimizu, H.; Takada, Y.; Fuku, A.; Tomiyasu, S.; Umemura, T.
miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors. Hemato 2022, 3, 373-384.
https://doi.org/10.3390/hemato3020026
AMA Style
Shibuta T, Shimizu H, Takada Y, Fuku A, Tomiyasu S, Umemura T.
miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors. Hemato. 2022; 3(2):373-384.
https://doi.org/10.3390/hemato3020026
Chicago/Turabian Style
Shibuta, Tatsuki, Honoka Shimizu, Yukichi Takada, Asuka Fuku, Satoshi Tomiyasu, and Tsukuru Umemura.
2022. "miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors" Hemato 3, no. 2: 373-384.
https://doi.org/10.3390/hemato3020026
APA Style
Shibuta, T., Shimizu, H., Takada, Y., Fuku, A., Tomiyasu, S., & Umemura, T.
(2022). miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors. Hemato, 3(2), 373-384.
https://doi.org/10.3390/hemato3020026